GlassScriptPhysician profile
Sara Abben
NPI 1760105274
$5,096.89
in general payments reported to CMS, 2019-2025
36 companies · $2,768 in 2025
The $2,768 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $1,903 · 2025: $2,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,096.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,326.76 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $599.17 | 2023-2025 | |
| Lilly USA, LLC | $580.27 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $390.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $352.09 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $335.65 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $245.24 | 2023-2025 | Rexulti |
| Medtronic, INC. | $108.44 | 2025 | Pulseselect |
| Glaxosmithkline, LLC. | $101.16 | 2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $92.32 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $90.76 | 2024-2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $71.47 | 2024-2025 | Keveyis |
| Phathom Pharmaceuticals, INC. | $68.73 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $64.93 | 2024-2025 | Veozah |
| Corium, LLC | $60.60 | 2023-2024 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.08 | 2023-2024 | |
| Dexcom, INC. | $51.11 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $44.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $43.91 | 2025 | Sunosi, Auvelity |
| Lundbeck LLC | $43.70 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $37.04 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $35.50 | 2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.51 | 2023 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $29.86 | 2023 | Amvuttra |
| Amgen INC. | $29.19 | 2024 | Otezla, Repatha, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Saluda Medical Americas, INC. | $22.87 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $21.53 | 2023 | |
| Radius Health, INC. | $21.16 | 2025 | Tymlos |
| Boston Scientific Corporation | $19.60 | 2025 | Watchman Flx |
| Eisai INC. | $17.70 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $16.17 | 2025 | |
| Bausch Health US, LLC | $16.07 | 2023 | Aplenzin |
| Cequr Corporation | $15.57 | 2023 | Cequr Simplicity |
| Organon LLC | $14.59 | 2025 | Nexplanon |
| Phadia US INC. | $14.21 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Abben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.